Omid Hamid, MD, discusses promising triplet combination under exploration in melanoma.
Omid Hamid, MD, director of the Melanoma Center and Phase I Immuno-Oncology Program at The Angeles Clinic and Research Institute, discusses promising triplet combination under exploration in melanoma.
Targeted therapy plays a significant role in modern management of patients with melanoma because it offers a survival advantage, explains Hamid. There is also a significant response in patients with brain metastases.
Further research is investigating the benefit of combining immunotherapy with targeted therapy in the form of a triplet regimen, says Hamid. Multiple randomized trials that are examining triplet therapies in this space are close to finishing and initial data show a progression-free survival benefit with this approach. For example, the TRILOGY trial is evaluating the use of cobimetinib (Cotellic), vemurafenib (Zelboraf), and atezolizumab (Tecentriq) versus just cobimetinib and vemurafenib in patients with advanced melanoma, concludes Hamid.